PTEN and glioblastoma: Coherently with this notion, despite Rapamycin exhibits antitumor activity in a phase I trial for patients with recurrent GBM and PTEN loss (NCT00047073) [110], phase II clinical trials for Rapamycin analogs did not achieve the same positive results (NCT00515086, NCT00016328, NCT00022724, and NCT00087451) [111,112,113,114,115].